Gel (repository corticotropin injection) to treat diabetic nephropathy (DN).
rights to Synacthen Depot from Novartis AG in 2013 violated antitrust laws by blocking competition for Questcor's drug Acthar
, which is used to treat several conditions including multiple sclerosis.
Gel in patients with Amyotropic Lateral Sclerosis
The addition of Questcor and its flagship product Acthar
for the treatment of severe autoimmune and inflammatory conditions will also substantially expand Mallinckrodt's portfolio of speciality brands, Mallinckrodt has said.
Gel that is used to treat certain disorders with an inflammatory component.
gel, an injectable formulation of adreno-corticotropin hormone, provided sufficient evidence that it was a safe and effective treatment for infantile spasms.
"), an injectable drug approved by the U.
The FTC complaint alleged that Questcors acquisition stifled competition by preventing any other company from using the Synacthen Depot assets to develop a synthetic ACTH drug for the United States, preserving Questcors monopoly and allowing it to maintain extremely high prices for Acthar
Gel (repository corticotropin injection) in rheumatoid arthritis (RA) patients with persistently active disease.
gel is expected to complement Mallinckrodt's growth portfolio of leading specialty pharmaceutical brands, including Ofirmev, Exalgo and Xartemis XR.
Specifically, defendants misrepresented and/or failed to disclose that: (i) the Company was disseminating false and misleading statements to the public concerning the efficacy of Acthar
as a treatment for multiple sclerosis and for nephrotic syndrome; (ii) the Company was marketing and promoting Acthar
aggressively as a treatment for these conditions, with an inadequate compliance program; and (iii) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.
Gel (repository corticotropin injection) as a treatment for amyotrophic lateral sclerosis (ALS).